MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
The posters are available on the Posters and Publications page of the Company’s website.
MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...
On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...